PTP1B inhibition may represent a promising drug target for NAFLD since its deficiency in mice enhanced insulin sensitivity and conferred resistance to diet-induced hepatic steatosis [17,18]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.